Oncology-focused biopharmaceuticals and cancer therapies by Nuvation Bio (NUVB)

  • Ezequiel Gomes
  • 17 hours ago
Nuvation Bio will present updated Phase 2 results at SNO2026 after muted trading session
Nuvation Bio said it plans to present updated results from its ongoing IDH1 inhibitor studies in IDH1-mutant glioma at SNO2026 in Philadelphia. The stock is little changed on the day, trading near ...
  • Mira Kyivska
  • 29.10.2026
Nuvation Bio expands Phase 3 SIGMA study in Europe: Can NUVB recover above the MA-20?
Nuvation Bio Inc. said its pivotal Phase 3 SIGMA trial of an investigational therapy for IDH1-mutant glioma will be expanded to six major European countries. The stock edges higher on the day, ...
  • Hanna Syniavska
  • 06.08.2026
Nuvation Bio stock consolidates near support with downside limited by oversold conditions
Nuvation Bio reported its second quarter 2026 financial results and provided a business update, according to a company post. At the same time, Nuvation Bio stock is down 1% on the day at $6.37.The ...
  • Emilio Ghigini
  • 04.08.2026
Nuvation Bio stock slips 2.69 percent to $6.16 as price action tests MA-20 resistance
Nuvation Bio said it will present new analyses from its pivotal TRUST-I and TRUST-II studies in patients with ROS1+ non-small cell lung cancer this fall at two major oncology congresses. At the ...